Patent · US Active

Mandelic hydrazides

US7776920B2 · kind B2 · utility

1Cited by

1References

8Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Rolf Gericke · Seeheim-Jugenheim, DE
Markus Klein · Weiterstadt, DE
Werner Mederski · Zwingenberg, DE
Norbert Beier · Reinheim, DE
Florian Lang · Gilching, DE

Key dates

Filing date	Jan 18, 2007
Grant date	Aug 17, 2010
Priority date	—
Expiry date	Jan 18, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel mandelic hydrazides of the formula (I), in which R1-R11 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.